The response rate to chemotherapy for BM of MM is 44%-59% for BRAF/MEK inhibitors (1), 20% for anti-PD-1 antibody agents (2), 46% for combined anti-PD-1/anti-CTLA-4 antibody agents (2), and 36% for immune checkpoint inhibitors (ICIs) and radiation therapy (3). The gene discussed is MAP2K7; the disease is Miyoshi myopathy.